^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
VENTANA PD-L1 (SP142) Assay

Company:
Roche
Type:
FDA Approved
Related tests:
VENTANA PD-L1 (SP142) Assay is a qualitative immunohistochemical assay using rabbit monoclonal anti-PD-L1 clone SP142 intended for use in the assessment of the programmed death-ligand 1 (PD-L1) protein in tumor cells and tumor-infiltrating immune cells in the formalin-fixed, paraffin-embedded (FFPE) tissues stained with OptiView DAB IHC Detection Kit and OptiView Amplification Kit on a BenchMark ULTRA instrument. PD-L1 expression in ≥ 50% TC or ≥ 10% IC determined by VENTANA PD-L1 (SP142) Assay in non-small cell lung cancer (NSCLC) patients may be associated with enhanced overall survival from TECENTRIQ (atezolizumab).
Cancer:
Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Urothelial Cancer
Gene:
PD-L1 (Programmed death ligand 1)
Drug:
Tecentriq (atezolizumab)
Method:
Immunohistochemistry (IHC)
Approvals
Date
Cancer
Gene
Drug
By